Navigation Links
Zydena is Efficacious in Once Daily Dosing for Erectile Dysfunction/Positive BPH Results
Date:11/18/2009

SEOUL, South Korea, Nov. 18 /PRNewswire/ -- Dong-A Pharmaceutical Co., Ltd. and Dong-A PharmTech, Co. Ltd. announced today that it has completed a 240 patient once-a-day dosing clinical study of udenafil, its new long acting phosphodiesterase type 5 (PDE-5) inhibitor for erectile dysfunction (ED). The multi-center study conducted in Korea was a randomized, double-blind, placebo-controlled study, designed to investigate the efficacy and safety of udenafil in patients with ED. Following a 4-week non-drug baseline period, 240 men with ED of broad etiology and severity were randomized to one of four treatment groups: Placebo, udenafil 25 mg, udenafil 50 mg or udenafil 75 mg. Patients took one tablet a day for 12 weeks with evaluations every 4 weeks. The primary efficacy endpoint was the change in the standard International Index of Erectile Function (IIEF) Erectile Function Domain (EF) score from baseline to final visit. The secondary efficacy endpoints were the change from the baseline in the mean vaginal penetration success rates and mean intercourse completion rates calculated from the Sexual Encounter Profile (SEP) questions 2 and 3. In addition a sub-group analysis was conducted to determine efficacy in the patients that had lower urinary tract symptoms associated with benign prostatic hyperplasia in addition to erectile dysfunction.

The primary efficacy endpoint for the 50 mg and 75 mg doses were statistically significant compared to placebo. The mean vaginal penetration success rates at 12 weeks (final visit) were 98.7% (75mg) and 90.3% (50mg) and both dose levels were statistically significant compared to placebo (p<0.01). The change from baseline to final visit in the mean intercourse completion rates were 73.5% (75mg) and 51.4% (50mg) significantly (p<0.0001) higher compared to the 23.5% observed in the placebo group. Patients reporting improved erections after the 12-week course of therapy were 88% (75mg), 75% (50mg) and 69.5% (25mg) and significantly (p<0.0001) higher compared to 35.6% in the placebo group. Forty-four percent of the patients in the 75 mg group shifted to normal erectile function (EF domain scores > 25) after 12 weeks on drug compared to 13.6% in the placebo group.

Approximately 65% in this ED trial also had lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH) as assessed by the validated International Prostate Symptom Score (IPSS) questionnaire. Efficacy for the relief of lower urinary tract symptoms due to BPH was achieved consistently in a dose dependent manner.

All three active dose levels were well-tolerated; the most frequently reported Treatment-emergent adverse events were flushing and headache and were mostly mild to moderate in severity. No myalgia, back pain, leg pain or vision disturbances were reported and no serious adverse events related to the drug were reported.

"We are extremely pleased with the results of this trial which clearly demonstrated the excellent efficacy and safety of Zydena® when taken once a day for erectile dysfunction and potentially for other more chronic indications. The efficacy trend seen for the relief of LUTS was also a plus", commented Mr. Dong Hyun Park, President and CEO of Dong-A PharmTech. Mr. Park indicated that Dong-A PharmTech will initiate a development program for the treatment of LUTS associated with BPH and for pulmonary arterial hypertension in early 2010 in the USA.

Dr. Ridwan Shabsigh, a leading urology researcher in the USA commented, "the results indicate that Zydena® is efficacious for ED at once daily dose levels of 50 mg and 75 mg, and the analysis of the IPSS in the men having LUTS presents the potential for the use of Zydena® as a once a day treatment for LUTS associated with BPH".

Also commenting is Dr. Jae Seung Paick, a member of the Board of Chairman at Societe Internationale d'Urologie. Dr. Paick commented that "developing long-acting PDE-5 inhibitors for LUTS associated with BPH is gaining a strong momentum. Udenafil, given its favorable efficacy and side effect profile is an excellent candidate for this new exciting therapeutic option for this troublesome condition affecting many of my patients."

Zydena® is currently marketed in Korea and Russia.

About Dong-A PharmTech Co., Ltd.

Dong-A PharmTech is a late-stage pharmaceutical company incorporated in Korea, focused on the development and commercialization of udenafil in North America and Russia and a number of other novel compounds globally.

Statements under the Private Securities Litigation Reform Act: with the exception of the historical information contained in this release, the matters described herein contain forward-looking statements that involve risk and uncertainties that may individually or mutually impact the matters herein described, including but not limited to FDA review and approval, product development and acceptance, manufacturing, competition, and/or other factors, which are outside the control of the Company.

    Mr. Won Geun KIM
    General Manager
    Tel: +82 2 560 8008
    Fax: + 82 2 563 6517
    Email: wgkim@donga.co.kr

SOURCE Dong-A PharmTech Co. Ltd.


'/>"/>
SOURCE Dong-A PharmTech Co. Ltd.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Study Shows Leconotide, an Investigative Calcium Channel Blocker, Has Potential as a Selective, Efficacious, Non-Opioid Pain Treatment
2. CardioGenics Holdings Inc. Featured in Medical Device Daily
3. Once-Daily INTUNIV(TM) (guanfacine) Extended Release Tablets Now Available in Pharmacies Nationwide
4. Schering-Plough Reports Potent Antiviral Activity With Narlaprevir (SCH 900518), an Investigational, Once-Daily Protease Inhibitor for Hepatitis C
5. New Data Show Once-Daily INTUNIV(TM) (guanfacine) Extended Release Tablets Demonstrated Significant ADHD Symptom Reduction when Assessed Using the Oppositional Subscale of the Conners ADHD Rating Scale
6. Transave Announces Positive Phase II Results For Once-Daily ARIKACE(TM) in the Treatment of Non-CF Bronchiectasis Patients Who Have Pseudomonas Lung Infections
7. Shire Announces FDA Approval of Once-Daily INTUNIV(TM) (guanfacine) Extended Release Tablets for the Treatment of ADHD in Children and Adolescents Aged 6 to 17
8. ISTA Pharmaceuticals Announces Positive Preliminary Phase 3 Clinical Results to Support sNDA Filing for Once-Daily Xibrom(TM) 0.09%
9. Analysis of Edoxaban Phase II Data Provides Insight Into Reduced Bleeding Events Seen in Once-Daily Dosing
10. Data Demonstrates Long-Term Reduction In Seizure Frequency With Novel Once Daily Anti-Epileptic Zebinix(R)
11. Study Results Present Efficacy and Safety Findings from the PHIRST-1 Study of Patients with Pulmonary Arterial Hypertension Taking Tadalafil Tablets Once Daily
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2016)... -- Niederländische Chirurgen haben eine innovative ... erlaubt, ihre Expertise weltweit zu teilen und so ... mit einer Instant-Messaging-Funktion und der Möglichkeit, in einem ... Afrika, Asien und den USA ... Information und Weiterbildung   "MDLinking ...
(Date:5/24/2016)... HENDERSON, Nev. , May 24, 2016  Diana ... painfully "eats" her organs from the inside out.  This ... her completely dependent on her children and grandchildren to ... of her wheelchair, Diana,s family cannot haul the wheelchair.  ... rides in the car, and Diana is left to ...
(Date:5/24/2016)... May 24, 2016  Joe Marziani has joined VMS BioMarketing as senior vice president ... today. In his new role, Marziani will lead the company,s business development and sales ... improve outcomes. Photo - http://photos.prnewswire.com/prnh/20160523/371089 ... ... ...
Breaking Medicine Technology:
(Date:5/27/2016)... ... May 27, 2016 , ... In response to meager public ... unaware of the plight of aphasia. In collaboration with the American Aphasia Association, ... , The link between stroke and aphasia is relatively unknown, but through collaboration ...
(Date:5/27/2016)... ... 2016 , ... With a team of certified experts, Validation ... from its GMP accreditation, Validation Center is also a registered authority of the ... staff. , Validation Center is ISO17025 accredited and only offers its clients the ...
(Date:5/26/2016)... ... May 26, 2016 , ... Intalere, the healthcare ... suppliers for its inaugural Member Conference at the Paris Hotel in Las Vegas, ... operational health of America’s healthcare providers. , The conference was highlighted by the ...
(Date:5/26/2016)... ... 2016 , ... Cardiac arrhythmia is a common complication following ... survival, reports a team of UPMC researchers in the largest study of its ... Thoracic and Cardiovascular Surgery, provide critical information that will hopefully lead to better ...
(Date:5/26/2016)... ... 2016 , ... An April Gallup survey found rising health care costs to ... Sun Health Senior Living (SHSL) may not share those same worries thanks to ... for the year, while holding the line on increasing their contributions, including premiums, deductibles ...
Breaking Medicine News(10 mins):